Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015

Brandon A Mahal; Santino Butler; Idalid Franco; Daniel E Spratt; Timothy R Rebbeck; Anthony V D'Amico; Paul L Nguyen

doi:10.1001/jama.2018.19941

Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015

JAMA. 2019 Feb 19;321(7):704-706. doi: 10.1001/jama.2018.19941.

Authors

Brandon A Mahal¹, Santino Butler¹, Idalid Franco¹, Daniel E Spratt², Timothy R Rebbeck¹, Anthony V D'Amico¹, Paul L Nguyen¹

Affiliations

¹ Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts.
² University of Michigan, Ann Arbor.

Abstract

This cancer epidemiology study uses SEER data to examine US trends in use of active surveillance, watchful waiting, radiotherapy, and surgical management of localized prostate cancer among men with low-, intermediate-, and high-risk disease treated between 2010 and 2015.

MeSH terms

Aged
Humans
Male
Middle Aged
Prostate-Specific Antigen / blood
Prostatectomy / trends
Prostatic Neoplasms / blood
Prostatic Neoplasms / epidemiology
Prostatic Neoplasms / therapy*
Radiotherapy / trends
Risk Factors
SEER Program
United States / epidemiology
Watchful Waiting / trends*

Substances

Prostate-Specific Antigen

Grants and funding

P20 CA233255/CA/NCI NIH HHS/United States